Phreesia Inc (PHR) Stock Forecast & Price Target

Phreesia is well positioned because its integrated patient intake, payments, and engagement platform is deeply embedded in provider workflows, serving over 4,400 healthcare providers and reaching ~1 in 7 U.S. patient visits, which supports durable demand and cross-sell opportunities. Its 2QF27 results showed $129.5M in revenue, 10% Y/Y growth, and $32.9M of adjusted EBITDA with a 25.4% margin, while operating cash flow of $18.3M and $23.5M of debt principal paydown strengthened the balance sheet. The outlook is further supported by patient payment processing growth, strong demand for AccessOne, and operating leverage from disciplined expense control and restructuring, all of which can drive profitable growth and margin expansion.

Phreesia is facing a weak fundamental setup because management held FY27 revenue guidance at $515M, implying only 7% Y/Y growth and less than 1% organic growth, while AccessOne’s ramp is now pushed into FY28 and subscription revenue growth was cut from +4% to (4%). The company also lowered FY28 revenue expectations to $540M and trimmed FY27 EBITDA to $129M, reflecting conservative assumptions around network solutions, AHSC additions, payment solutions growth, and rising AI and hiring costs despite restructuring benefits. With lower spend commitments in network solutions, execution risk at AccessOne, and competitive pressure from larger vendors like Epic and Oracle, the path to durable growth and free cash flow looks increasingly uncertain.